7524 related articles for article (PubMed ID: 22016836)
1. Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects.
Shahshahan MA; Beckley MN; Jazirehi AR
Am J Cancer Res; 2011; 1(7):913-24. PubMed ID: 22016836
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibitors in the treatment of B-cell malignancies.
Schenkein D
Clin Lymphoma; 2002 Jun; 3(1):49-55. PubMed ID: 12141956
[TBL] [Abstract][Full Text] [Related]
3. Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment.
Montagut C; Rovira A; Mellado B; Gascon P; Ross JS; Albanell J
Drugs Today (Barc); 2005 May; 41(5):299-315. PubMed ID: 16082428
[TBL] [Abstract][Full Text] [Related]
4. The proteasome: a novel target for anticancer therapy.
Montagut C; Rovira A; Albanell J
Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
Mitsiades CS; McMillin D; Kotoula V; Poulaki V; McMullan C; Negri J; Fanourakis G; Tseleni-Balafouta S; Ain KB; Mitsiades N
J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420
[TBL] [Abstract][Full Text] [Related]
6. The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib.
Cvek B; Dvorak Z
Curr Pharm Des; 2011; 17(15):1483-99. PubMed ID: 21504411
[TBL] [Abstract][Full Text] [Related]
7. The proteasome as a target for cancer therapy.
Voorhees PM; Dees EC; O'Neil B; Orlowski RZ
Clin Cancer Res; 2003 Dec; 9(17):6316-25. PubMed ID: 14695130
[TBL] [Abstract][Full Text] [Related]
8. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
[TBL] [Abstract][Full Text] [Related]
9. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
Yerlikaya A; Erin N
Int J Mol Med; 2008 Dec; 22(6):817-23. PubMed ID: 19020781
[TBL] [Abstract][Full Text] [Related]
10. Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs.
Mujtaba T; Kanwar J; Wan SB; Chan TH; Dou QP
Int J Mol Med; 2012 Jan; 29(1):102-6. PubMed ID: 22012631
[TBL] [Abstract][Full Text] [Related]
11. Discovery, Development, and clinical applications of bortezomib.
Jung L; Holle L; Dalton WS
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
[TBL] [Abstract][Full Text] [Related]
12. Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells.
Yu J; Tiwari S; Steiner P; Zhang L
Cancer Biol Ther; 2003; 2(6):694-9. PubMed ID: 14688479
[TBL] [Abstract][Full Text] [Related]
13. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
Zhu H; Zhang L; Dong F; Guo W; Wu S; Teraishi F; Davis JJ; Chiao PJ; Fang B
Oncogene; 2005 Jul; 24(31):4993-9. PubMed ID: 15824729
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation.
Li C; Chen S; Yue P; Deng X; Lonial S; Khuri FR; Sun SY
J Biol Chem; 2010 May; 285(21):16096-104. PubMed ID: 20335171
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress.
Fribley A; Wang CY
Cancer Biol Ther; 2006 Jul; 5(7):745-8. PubMed ID: 16861900
[TBL] [Abstract][Full Text] [Related]
16. The ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib.
Milano A; Perri F; Caponigro F
Onco Targets Ther; 2009 Feb; 2():171-8. PubMed ID: 20616904
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
Chen D; Frezza M; Schmitt S; Kanwar J; Dou QP
Curr Cancer Drug Targets; 2011 Mar; 11(3):239-53. PubMed ID: 21247388
[TBL] [Abstract][Full Text] [Related]
18. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
[TBL] [Abstract][Full Text] [Related]
19. Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.
Wang Y; Rishi AK; Puliyappadamba VT; Sharma S; Yang H; Tarca A; Dou QP; Lonardo F; Ruckdeschel JC; Pass HI; Wali A
Cancer Chemother Pharmacol; 2010 Aug; 66(3):455-66. PubMed ID: 19960346
[TBL] [Abstract][Full Text] [Related]
20. The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib.
Engür S; Dikmen M
Acta Clin Belg; 2017 Dec; 72(6):391-398. PubMed ID: 28327055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
